The capital injection will help the company to further develop its handheld robotic interventional platform. Credit: Gerain0812/Shutterstock.

Healthcare technology company Mendaera has secured $73m in a Series B financing round, with the investment to be used for expanding the use of robotics and AI in mainstream medical procedures.

Threshold Ventures led the funding round, which saw contributions from Lux Capital, PFM Health Sciences, and Intuitive Surgical and Auris Health founder Fred Moll.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The capital injection will enable Mendaera to advance its mission of making complex technologies available for foundational medical procedures.

The company will focus on refining a handheld robotic interventional platform that integrates robotics, AI, real-time imaging, and virtual connectivity.

This platform is designed to be widely accessible, enhancing the capabilities of healthcare providers across various specialities and service sites.

See Also:

The newly acquired funds will be allocated to completing the development of Mendaera’s robotic technology, expediting the advancement of its AI and connectivity features, and initiating the clinical introduction of its new platform.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Mendaera founder and CEO Josh DeFonzo said: “Traditional surgical robots have established footing in the operating room. But robotics and AI have evolved to a point where we can deliver broader benefits across all parts of the healthcare system and enable higher standards of care for more patients.

“We believe that our technology will allow healthcare systems and providers to provision medical procedures at scale, enhancing patient experience, increasing access to high-quality care, reducing overall cost, and improving healthcare provider satisfaction.”

The company expanded its technology portfolio earlier in the year through the acquisition of telepresence technology from Avail Medsystems.

Last year, Mendaera entered a commercial agreement with Butterfly Network, an enterprise specialising in point-of-care ultrasound technology, for the commercialisation of a next-generation interventional robotic system.